Date: 2015-08-03
Type of information: Establishment of a new subsidiary in the EU
Compound: multiple prespecified and undisclosed biosimilar or biobetter monoclonal antibodies
Company: Sorrento Therapeutics (USA - CA) Mabtech (China)
Therapeutic area: Autoimmune diseases
Type agreement: licensing development commercialisation
Action mechanism: monoclonal antibody/biosimilar.
Disease:
Details: * On August 3, 2015, Sorrento Therapeutics announced that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China. Under the terms of the agreement, Sorrento will develop and market these 4 monoclonal antibodies (mAbs) for the North American, European and Japanese market. Each of the mAbs has completed a Phase III study; two are currently in registration for marketing approval in China, while the other two are under data analyses for subsequent NDA submission in China. One of the biobetter mAbs is based on a Top 10-selling oncology drug and the other a Top 5-selling antibody to treat auto-immune diseases. Together these 4 mAbs target an established market with combined annual global sales in 2014 in excess of $13 Billion.
Financial terms:
Latest news:
